| Literature DB >> 35956345 |
Xue Wang1, Lu Tang1, Wenxin Ping1, Qiaofen Su1, Songying Ouyang1, Jingqian Su1.
Abstract
Globally, the incidence of diabetes is increasing annually, and China has the largest number of patients with diabetes. Patients with type 2 diabetes need lifelong medication, with severe cases requiring surgery. Diabetes treatment may cause complications, side-effects, and postoperative sequelae that could lead to adverse health problems and significant social and economic burdens; thus, more efficient hypoglycemic drugs have become a research hotspot. Glucose metabolism disorders can promote diabetes, a systemic metabolic disease that impairs the function of other organs, including the heart, liver, and kidneys. Cyclocarya paliurus leaves have gathered increasing interest among researchers because of their effectiveness in ameliorating glucose metabolism disorders. At present, various compounds have been isolated from C. paliurus, and the main active components include polysaccharides, triterpenes, flavonoids, and phenolic acids. C. paliurus mainly ameliorates glucose metabolism disorders by reducing glucose uptake, regulating blood lipid levels, regulating the insulin signaling pathway, reducing β-cell apoptosis, increasing insulin synthesis and secretion, regulating abundances of intestinal microorganisms, and exhibiting α-glucosidase inhibitor activity. In this paper, the mechanism of glucose metabolism regulation by C. paliurus was reviewed to provide a reference to prevent and treat diabetes, hyperlipidaemia, obesity, and other metabolic diseases.Entities:
Keywords: Cyclocarya paliurus; glucose metabolism; insulin secretion; metabolic diseases; type 2 diabetes
Mesh:
Substances:
Year: 2022 PMID: 35956345 PMCID: PMC9370411 DOI: 10.3390/nu14153169
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 6.706
Figure 1Chemical and structural formula of the Cyclocarya paliurus polysaccharide.
The mechanism of action of the different Cyclocarya paliurus extracts on type 2 diabetes mellitus.
| Active Ingredient | Extraction Method | Extraction Conditions | Biological Function | Possible Mechanism | Model | Reference | |
|---|---|---|---|---|---|---|---|
| In Vivo | In Vitro | ||||||
| Polysaccharide | Water extraction |
Dry leaves powder; Solid residue (hot water); Crude polysaccharide (dialysis, protein removal, decolorization chromatographic column); Purified polysaccharide. | Regulation of intestinal microorganisms | SCFAs→GLP-1→Insulin signaling pathway | Wistar rats | [ | |
| Polysaccharide | Alcohol extraction |
Dry leaves with 80% ethanol for 24 h; Residue (dry, soak in distilled water, filter); Filtrate (decompression, concentration); Filtrate (add anhydrous ethanol, centrifuged); C. paliurus polysaccharide. | Regulation of intestinal microorganisms | SCFAs→SCFAs-GLP1/PYY | SD rats | [ | |
| Triterpene | Alcohol extraction |
Dry leaves with 80% ethanol for 24 h; Extractive (decompression, concentration, degreased with petroleum ether, partitioned with chloroform); Triterpenic acid-rich fraction. | Improvement of insulin resistance | PI3K→Akt→ | C57BL/6J mice | HepG2 cells induced by 100 mM PA | [ |
| Triterpene | Alcohol extraction |
Dry leaves with 70% EtOH at room temperature; Crude extract suspended in H2O, successively partitioned with petroleum ether, EtoAc, and n-BuOH. | Improvement of islet resistance | AMPK→P38→ | C2C12 cells | [ | |
| Triterpene | Alcohol extraction |
Dry leaves with 80% alcohol; Extractive (decompression, concentration, degreased with petroleum ether, partitioned with chloroform); Chloroform fraction (dissolved in chloroform, partitioned with NaOH, neutralizing the aqueous phase with HCl, re-extracted with chloroform); Triterpenic acid-rich fraction. | Hypolipidemia | TNF-α→MAPK→apoB48 | SD rats | [ | |
| Triterpene | Alcohol extraction + chloroform extraction |
Dry leaves with 80% ethanol; Extractive (decompression, concentration, partitioned with chloroform); | Hypolipidemia | SREBP→ACC1/ | SD rats | [ | |
| Flavone | Water extraction |
Dry leaves with 80% ethanol; Extractive (decompression, concentration, degreased with petroleum ether); Freeze-dried after decompression and concentration. Crude extract. | Reduction in appetite | PI3K/Akt→ | SHR/cp rats | [ | |
| Flavone | Water extraction |
Dry leaves boiled with water; Aqueous extract (concentrated and dried under reduced pressure); Crude extract. | Inhibition of islet cell apoptosis | p38→ERK→JNK→Akt | C57BL/6J mice | NIT-1 cells | [ |
| Flavone | Water extraction |
Dry leaves boiled with water; Aqueous extract (concentrated and dried under reduced pressure); Crude extract. | Inhibition of the α-glucosidase activity | C57BL/6J mice | [ | ||
Abbreviations: NPY, neuropeptide Y; POMC, proopiomelanocortin; SCFAs, short-chain fatty acids.
Therapeutic effects of small molecules in Cyclocarya paliurus on type 2 diabetes mellitus.
| Classification | Name (9) | Structure (9) | Relevant Indicators | Model | Reference | |
|---|---|---|---|---|---|---|
| In Vivo | In Vitro | |||||
| Flavone | Fisetin |
| FBG, Serum insulin, Glycosylation of red cells | Wistar rats | [ | |
| Kaempferol |
| FBG, GSK3β phosphorylation, Liver pyruvate carboxylase activity, gluconeogenesis | C57BL/6 mice | [ | ||
| Quercetin |
| FBG, Pancreatic iron deposition, Pancreatic PBC iron death, ROS, Serum insulin | C57BL/6 mice | [ | ||
| Isorhamnetin |
| FBG, Serum insulin, HOMA-IR, BW, blood fat, LncRNA-RP11-773H22.4 | Wistar rats | [ | ||
| Naringenin |
| FBG, BW, Impaired glucose tolerance, Serum insulin, HOMA-IR, ROS | C57BLKsJ db/+ mice | [ | ||
| Apigenin |
| Renal injury, Pro-inflammatory gene expression, CD38, Sirt3, ROS | Zucker rats | [ | ||
| Triterpene | Oleanolic acid |
| BW, Liver weight, LDL, TG, SREBP, total bilirubin, Liver injury | SD rats | [ | |
| Maslinic acid |
| BW, FBG, food intake, urinary albumin, Renal injury, kidney ROS | C57BL/6 mice | [ | ||
| (20S,24R)-20,24-Epoxy-25-hydroxy-12β-(α- l -arabinopyranosyloxy)-3,4-seco-dammara-4(28)-en-3-oic acid |
| AMP (AMPK)-p38 access, Glucose uptake | C2C12 cells | [ | ||
Abbreviations: BW, body weight; FBG, fasting blood glucose; HOMA-IR, insulin resistance index; LDL, low-density lipoprotein; PBC, pancreatic β cells; ROS, reactive oxygen species; SD, Sprague–Dawley; STZ, streptozocin; TG, triacylglycerol.
Figure 2The mechanism of action of Cyclocarya paliurus flavonoids with respect to decreasing appetite. ↑: increase; ↓: decline.
Figure 3The mechanism of action of Cyclocarya paliurus extract with respect to inhibiting lipid synthesis and alleviating pathological insulin resistance in liver cells.
Figure 4The mechanism of action of Cyclocarya paliurus extract with respect to lowering blood glucose and lipid levels through intestinal metabolism. ↑: increase; ↓: decline.
Figure 5The mechanism of action of Cyclocarya paliurus extract with respect to inhibiting pathological insulin resistance in white adipocytes and muscle cells.
Figure 6The mechanism of action of Cyclocarya paliurus flavone with respect to alleviating islet cell apoptosis and relatively insufficient insulin secretion caused by glycolipid toxicity.